Workflow
SHKK(900943)
icon
Search documents
开开B股:2024年报净利润0.35亿 同比下降10.26%
Tong Hua Shun Cai Bao· 2025-04-29 10:02
Financial Performance - The basic earnings per share decreased by 12.5% from 0.1600 yuan in 2023 to 0.1400 yuan in 2024 [1] - The total revenue increased by 18.27%, rising from 9.25 billion yuan in 2023 to 10.94 billion yuan in 2024 [1] - The net profit decreased by 10.26%, from 0.39 billion yuan in 2023 to 0.35 billion yuan in 2024 [1] - The return on equity fell by 14.92%, from 6.77% in 2023 to 5.76% in 2024 [1] - The net asset per share increased by 4.08%, from 2.45 yuan in 2023 to 2.55 yuan in 2024 [1] - The undistributed profits per share increased by 7.89%, from 1.14 yuan in 2023 to 1.23 yuan in 2024 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 80.9689 million shares, accounting for 33.74% of the circulating shares, with an increase of 4.5409 million shares compared to the previous period [1] - Shanghai Kaikai (Group) Co., Ltd. remains the largest shareholder with 64.4098 million shares, representing 26.84% of the total share capital [2] - New entrants among the top shareholders include Zhao Liqian, Sun Chengyuan, and Zhao Guohua, holding 2.3962 million shares, 2.2533 million shares, and 1.6120 million shares respectively [2] - Goldman Sachs LLC and other shareholders have exited the top ten list [2] Dividend Distribution - The company announced a dividend distribution of 0.44 yuan per share (including tax) [3]
开开实业(600272) - 关于2024年度向特定对象发行A股股票预案及相关文件修订情况说明的公告
2025-02-28 10:00
| 股票代码:600272 | 股票简称:开开实业 编号:2025-007 | | --- | --- | | 900943 | 开开 B 股 | 上海开开实业股份有限公司 关于 2024 年度向特定对象发行 A 股股票预案及 相关文件修订情况说明的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 上海开开实业股份有限公司(以下简称:"公司")于 2024 年 5 月 20 日召开的公司第十届董事会第十八次会议、第十届监事会第十二 次会议,于 2024 年 6 月 28 日召开的 2023 年年度股东大会,审议通 过了关于公司 2024 年度向特定对象发行 A 股股票(以下简称"本次 发行")的相关议案。(具体内容详见公司 2024 年 5 月 21 日、6 月 29 日《上海证券报》《香港商报》和上海证券交易所网站 www.sse.com.cn 公告)。 2025 年 2 月 28 日,公司召开第十届董事会第二十三次会议、第 十届监事会第十六次会议,审议通过了《关于调整公司 2024 年度向 特定对象发行 A 股股票方案 ...
开开实业(600272) - 第十届监事会第十六次会议决议公告
2025-02-28 10:00
第十届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 上海开开实业股份有限公司(以下简称:"公司")第十届监事会 第十六次会议通知和会议文件于 2025 年 2 月 24 日以书面、电话及电 子邮件等方式发出,会议于 2025 年 2 月 28 日在公司会议室以现场表 决方式召开。本次会议应到监事 3 名,实到监事 3 名。本次会议由监 事会主席单丹丹女士主持,会议的召开符合《中华人民共和国公司法》 等有关法律、行政法规、部门规章、规范性文件和《公司章程》的有 关规定。会议审议通过了如下议案: 一、关于调整公司 2024 年度向特定对象发行 A 股股票方案的议 案 | 股票代码:600272 | 股票简称:开开实业 编号:2025-004 | | --- | --- | | 900943 | 开开 B 股 | 上海开开实业股份有限公司 公司本次发行方案的具体调整内容如下: (一)定价基准日、发行价格及定价原则 调整前: "本次发行的定价基准日为公司第十届董事会第十八次会议决 议公告日,发行价格为 ...
开开实业(600272) - 第十届董事会第二十三次会议决议公告
2025-02-28 10:00
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 上海开开实业股份有限公司(以下简称:"公司")第十届董事会 第二十三次会议通知和会议文件于 2025 年 2 月 24 日以书面、电话及 电子邮件等方式发出,会议于 2025 年 2 月 28 日在公司会议室以现场 表决方式召开。本次会议应到董事 9 名,实到董事 9 名,3 名监事及 其他高级管理人员列席了会议。本次会议由董事长庄虔贇女士主持, 会议的召开符合《中华人民共和国公司法》等有关法律、行政法规、 部门规章、规范性文件和《公司章程》的有关规定。会议通过如下议 案: | 股票代码:600272 | 股票简称:开开实业 编号:2025-003 | | --- | --- | | 900943 | 开开 B 股 | 上海开开实业股份有限公司 第十届董事会第二十三次会议决议公告 公司本次发行方案的具体调整内容如下: (一)定价基准日、发行价格及定价原则 调整前: 一、关于调整公司 2024 年度向特定对象发行 A 股股票方案的议 案 由于本议案涉及关联交易,根据《上海证券交 ...
开开实业(600272) - 关于向特定对象发行A股股票股东权益拟发生变动的提示性公告
2025-02-28 09:47
股票代码:600272 股票简称:开开实业 编号:2025—010 900943 开开 B 股 上海开开实业股份有限公司 关于向特定对象发行 A 股股票 股东权益拟发生变动的提示性公告 本次发行相关事宜尚需经上海证券交易所审核通过并经中国 证券监督管理委员会同意注册后方可实施。 一、本次股东权益变动基本情况 公司拟向共计 1 名特定发行对象上海开开(集团)有限公司(以 下简称:"开开集团")发行 19,651,945 股 A 股股票,不超过本次发行 前公司总股本的 30%,募集资金总额不超过人民币 159,770,312.85 元 (含本数)。开开集团将以自有资金或自筹资金认购公司本次发行股 份。本次权益变动不会导致公司控股股东及实际控制人发生变化。 本次发行对象为开开集团,系公司的控股股东,属于公司关联方。 因此,本次发行构成关联交易。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 1、2025 年 2 月 26 日,公司召开独立董事 2025 年第二次会议, 以 3 票同意、0 票反对、0 票弃权的表决结果审议通过了 ...
开开实业:关于参加2024年上海辖区上市公司集体接待日暨中报业绩说明会召开情况的公告
2024-09-13 09:21
| 股票代码:600272 | 股票简称:开开实业 编号:2024—053 | | --- | --- | | 900943 | 开开 B 股 | 上海开开实业股份有限公司 关于参加 2024 年上海辖区上市公司集体接待日 暨中报业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 上海开开实业股份有限公司(以下简称:"公司")(以下简称 "公司")于 2024 年 9 月 13 日(星期五)下午 14:00-16:30 参加由 上海上市公司协会与深圳市全景网络有限公司联合举办的"2024 年 上海辖区上市公司集体接待日暨中报业绩说明会",以网络文字互动 方式就投资者关心的问题进行了交流。关于本次业绩说明会的召开事 项,详见公司 2024 年 9 月 7 日在《上海证券报》《香港商报》和上 海证券交易所网站(www.sse.com.cn)2024-052 号公告。现将召开情 况公告如下: 一、业绩说明会召开情况 召开时间:2024 年 9 月 13 日(周五)14:00-16:30,其中网络文 字互动交 ...
开开实业:关于参加2024年上海辖区上市公司集体接待日暨中报业绩说明会的公告
2024-09-06 07:35
| 股票代码:600272 | 股票简称:开开实业 编号:2024—052 | | --- | --- | | 900943 | 开开 B 股 | 上海开开实业股份有限公司 关于参加 2024 年上海辖区上市公司集体接待日 暨中报业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: ●会议召开时间:2024 年 9 月 13 日(周五)14:00-16:30,其中网 络文字互动交流时间为 15:00-16:30 ●会议召开地点: "全景路演"网站 (https://rs.p5w.net/html/143790.shtml) ●会议召开方式:网络文字互动方式 ●投资者可于2024年9月9日(周一)至9月11日(周三)16:00前 通过公司邮箱dm@chinesekk.com进行提问。公司将在业绩说明会上 对投资者普遍关注的问题进行回答。 三、参加人员 董事、总经理: 刘光靓先生 上海开开实业股份有限公司(以下简称"公司")已于《上海证 券报》《香港商报》及上海证券交易所网站(www.sse.com ...
开开B股(900943) - 2024 Q2 - 季度财报
2024-08-16 09:35
[Definitions](index=4&type=section&id=第一节%20释义) This chapter defines key terms, company abbreviations, and regulatory information, providing a foundational understanding of the report [Definitions of Common Terms](index=4&type=section&id=常用词语释义) This chapter defines professional terms, company entity abbreviations, regulatory bodies, and relevant regulations used in the report, providing a basis for understanding the report content [Company Profile and Key Financial Indicators](index=5&type=section&id=第二节%20公司简介和主要财务指标) This section provides the company's basic information and a summary of its key financial performance and indicators [Company Basic Information](index=5&type=section&id=一、%20公司信息) This chapter provides the company's basic business registration information, including names, legal representative, contact details, and addresses, noting an office address change during the reporting period - During the reporting period, the company's office address changed from "Building 3, 1-3rd Floor, No. 421 Haifang Road, Shanghai" to "No. 678 Changping Road, Jing'an District, Shanghai"[10](index=10&type=chunk) [Key Accounting Data and Financial Indicators](index=6&type=section&id=七、%20公司主要会计数据和财务指标) During the reporting period, the company's operating revenue and net profit attributable to shareholders both achieved significant growth, but net profit after deducting non-recurring gains and losses sharply declined by 60.32% due to a large housing expropriation compensation Main Accounting Data | Main Accounting Data | Current Period (Jan-Jun) (RMB) | Prior Period (RMB) | Current Period vs. Prior Period Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 489,520,495.53 | 390,695,063.33 | 25.29% | | Net Profit Attributable to Shareholders of Listed Company | 31,009,018.96 | 16,921,435.33 | 83.25% | | Net Profit Attributable to Shareholders of Listed Company After Deducting Non-recurring Gains and Losses | 3,293,810.28 | 8,300,642.02 | -60.32% | | Net Cash Flow from Operating Activities | -27,934,426.71 | -20,721,631.19 | Not Applicable | | | **Current Period End (RMB)** | **Prior Year End (RMB)** | **Current Period End vs. Prior Year End Change (%)** | | Net Assets Attributable to Shareholders of Listed Company | 614,929,362.24 | 595,827,343.28 | 3.21% | | Total Assets | 1,392,504,076.32 | 1,326,712,627.84 | 4.96% | Main Financial Indicators | Main Financial Indicators | Current Period (Jan-Jun) | Prior Period | Current Period vs. Prior Period Change (%) | | :--- | :--- | :--- | :--- | | Basic Earnings Per Share (RMB/share) | 0.128 | 0.070 | 82.86% | | Basic Earnings Per Share After Deducting Non-recurring Gains and Losses (RMB/share) | 0.014 | 0.034 | -58.82% | | Weighted Average Return on Net Assets (%) | 5.07% | 2.95% | Increased by 2.12 percentage points | | Weighted Average Return on Net Assets After Deducting Non-recurring Gains and Losses (%) | 0.54% | 1.45% | Decreased by 0.91 percentage points | - The main reason for the company's decline in non-recurring net profit is the adjustment in the domestic consumer market, leading to more cautious consumption of high-end tonics and other products, resulting in lower revenue and gross profit for related products[15](index=15&type=chunk) - The significant increase in net profit is due to the recognition of **RMB 28.4393 million** in housing expropriation compensation income during the reporting period, which is a non-recurring gain or loss[15](index=15&type=chunk) [Analysis of Non-recurring Gains and Losses](index=7&type=section&id=九、%20非经常性损益项目和金额) During the reporting period, total non-recurring gains and losses amounted to **RMB 27.7152 million**, which is the core reason why net profit attributable to shareholders was significantly higher than net profit after deducting non-recurring gains and losses, with disposal gains/losses from non-current assets being the largest item at **RMB 28.4692 million** Non-recurring Gains and Losses Items | Non-recurring Gains and Losses Item | Amount (RMB) | | :--- | :--- | | Disposal Gains/Losses from Non-current Assets | 28,469,249.30 | | Government Grants Included in Current Profit/Loss | 5,553,009.18 | | Fair Value Change Gains/Losses of Financial Assets/Liabilities | 1,149,693.48 | | Other Non-operating Income/Expenses and Others | 920,969.61 | | Less: Income Tax Impact | 8,375,828.57 | | Less: Impact of Minority Interests (After Tax) | 1,884.32 | | **Total** | **27,715,208.68** | [Management Discussion and Analysis](index=8&type=section&id=第三节%20管理层讨论与分析) This section provides an in-depth discussion of the company's industry, core business operations, competitive advantages, and potential risks [Industry and Main Business Overview](index=8&type=section&id=一、报告期内公司所属行业及主营业务情况说明) The company operates under a dual-main business model of pharmaceutical distribution and services, and apparel wholesale and retail, with both "Leiyunshang" and "Kaikai" brands being "China Time-honored Brands" - The company's main business operates under a dual-main business model: - **Pharmaceutical Segment**: Primarily wholesale, retail, and health services, covering medicines, medical devices, etc., and transforming towards comprehensive health services[23](index=23&type=chunk) - **Apparel Segment**: Engaged in wholesale, retail, and custom business of "Kaikai" brand shirts, wool sweaters, and other series[23](index=23&type=chunk) - The pharmaceutical segment's operating model revolves around the "big health" industry, focusing on digital development through the "Four Clouds" project (Cloud Pharmacy, Traditional Chinese Medicine Cloud, Cloud Health, Cloud Medicine City)[26](index=26&type=chunk) - The company's two major brands, "Leiyunshang" and "Kaikai", are both "China Time-honored Brands", with their brand value recognized by the market[28](index=28&type=chunk) - "Shang Lei" brand products rank among the top in similar traditional Chinese medicine products in the city, and "Kaikai" brand is a "China Well-known Trademark"[28](index=28&type=chunk) [Analysis of Core Competencies](index=9&type=section&id=二、报告期内核心竞争力分析) The company's core competencies are reflected in its talent, brand, regional presence, and customer network advantages, including a professional team, two "China Time-honored Brands", a strategic location in Shanghai, and stable relationships with medical institutions - **Talent Advantage**: Possesses **136** mid-to-senior professional and technical personnel and multiple high-skilled talent training bases and workshops[29](index=29&type=chunk) - **Brand Advantage**: Owns "Leiyunshang" and "Kaikai", two "China Time-honored Brands", with "Shang Lei" self-owned brand tonic series products achieving annual sales exceeding **RMB 100 million**[31](index=31&type=chunk) - **Regional and Customer Advantage**: Business is rooted in Shanghai's Jing'an District core business circle, with stable customer traffic[32](index=32&type=chunk) - The pharmaceutical segment has established stable business relationships with numerous medical institutions across the city and radiates to the Yangtze River Delta[33](index=33&type=chunk) [Discussion and Analysis of Operations](index=10&type=section&id=三、经营情况的讨论与分析) In the first half of 2024, the company pursued its "big health" transformation, initiated A-share refinancing, and deepened apparel reforms, achieving revenue and net profit growth despite a decline in non-recurring net profit due to market changes Financial Indicators | Financial Indicator | June 30, 2024 / First Half | vs. Beginning of Year / Prior Period | Increase/Decrease | | :--- | :--- | :--- | :--- | | Total Assets | RMB 1.393 billion | Increased by RMB 65.7915 million | 4.96% | | Net Assets Attributable to Parent Company | RMB 615 million | Increased by RMB 19.1021 million | 3.21% | | Operating Revenue | RMB 490 million | Increased by RMB 98.8254 million | 25.29% | | Net Profit Attributable to Parent Company | RMB 31.009 million | Increased by RMB 14.0876 million | 83.25% | | Net Profit After Deducting Non-recurring Gains and Losses | RMB 3.2938 million | Decreased by RMB 5.0068 million | -60.32% | - The company initiated a "private placement of A-shares" refinancing project, aiming to provide financial support for the "big health" industry layout and increase the state-controlled shareholder's stake to over **33.4%**[39](index=39&type=chunk) - The company actively explores the "Digital + Health" innovation model, accelerating the optimization of the "Four Clouds" platform functions, with traditional Chinese medicine decoction pieces wholesale business revenue growing by nearly **30%** in the first half of the year[41](index=41&type=chunk) - The company is expanding into new medical service areas; the "Leiyunshang Xiqu Clinic Dental Department Project" began trial operation in early July, aiming to create a "one-stop" full-cycle oral health management service[41](index=41&type=chunk) [Analysis of Main Business](index=14&type=section&id=四、报告期内主要经营情况) This chapter details financial statement account changes, non-operating profit impacts, asset and liability status, and investment activities, highlighting that revenue growth was driven by medical consumables and reagents supply chain business, and asset disposal gains were a key non-operating factor for profit increase [Analysis of Changes in Financial Statement Accounts](index=14&type=section&id=1%20财务报表相关科目变动分析表) During the reporting period, operating revenue increased by 25.29% year-on-year, mainly due to the growth in medical consumables and reagents supply chain business, while asset disposal gains surged by 1,849,364.27% due to housing expropriation compensation | Account | Current Period Amount (RMB) | Prior Period Amount (RMB) | Change Ratio (%) | Main Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 489,520,495.53 | 390,695,063.33 | 25.29 | Increase in medical consumables and reagents supply chain business revenue | | Operating Cost | 397,186,647.60 | 297,440,370.70 | 33.53 | Increased with sales revenue | | Asset Disposal Gains | 28,485,263.76 | 1,540.19 | 1,849,364.27 | Recognition of housing expropriation compensation income | | Net Cash Flow from Investing Activities | 25,883,454.68 | -29,650,329.02 | Not Applicable | Received housing expropriation compensation | | Credit Impairment Losses | -1,929,841.64 | -10,393,492.45 | Not Applicable | Reduced provision for bad debts due to smaller increase in USD exchange rate | [Analysis of Assets and Liabilities](index=15&type=section&id=(三)%20资产、负债情况分析) Total assets at the end of the period increased by 4.96% from the beginning of the year, with significant increases in prepaid accounts, long-term deferred expenses, and right-of-use assets due to business procurement and the dental department project, while other receivables decreased significantly due to housing relocation funds | Item Name | Current Period End Amount (RMB) | Prior Year End Amount (RMB) | Change Ratio (%) | Main Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Prepaid Accounts | 2,132,706.32 | 1,280,122.81 | 66.60 | Increased prepaid purchases in pharmaceutical and apparel segments | | Other Receivables | 4,099,737.88 | 25,187,680.64 | -83.72 | Received housing relocation funds receivable at prior year-end | | Construction in Progress | 1,066,813.20 | 2,596,039.50 | -58.91 | Dental department expansion project completed and transferred out | | Long-term Deferred Expenses | 7,158,308.66 | 2,894,345.74 | 147.32 | Expenditures related to dental department expansion project transferred in | [Analysis of Major Holding and Participating Companies](index=18&type=section&id=(六)%20主要控股参股公司分析) The company's main profits come from its wholly-owned subsidiary, Shanghai Leiyunshang Pharmaceutical Xiqu Co., Ltd., which achieved a net profit of **RMB 35.56 million** in the first half of the year, and its holding subsidiary, Shanghai Leixi Jingyi Supply Chain Management Co., Ltd., which contributed **RMB 10.89 million** in net profit - **Shanghai Leiyunshang Pharmaceutical Xiqu Co., Ltd. (Wholly-owned Subsidiary)**: As the operating entity for the pharmaceutical segment, it achieved operating revenue of **RMB 459 million** and net profit of **RMB 35.5599 million** in the first half of 2024[51](index=51&type=chunk) - **Shanghai Leixi Jingyi Supply Chain Management Co., Ltd. (Holding Subsidiary)**: The consumables and reagents supply chain business operated stably, achieving operating revenue of **RMB 189 million** and net profit of **RMB 10.8936 million** in the first half of 2024[52](index=52&type=chunk) [Potential Risks](index=18&type=section&id=五、其他披露事项) The company faces three main risks: the long cultivation period and market uncertainties of its "big health" strategic transformation, the potential shrinking of traditional pharmaceutical business due to macro policies like centralized drug procurement, and intense competition in the highly market-oriented apparel and pharmaceutical retail industries - **Transformation and Development Risk**: The company's "big health" strategic transformation-related businesses require a longer cultivation period, with market development uncertainties, potentially negatively impacting profits in the short term[54](index=54&type=chunk) - **Macro Policy Risk**: Policies such as centralized drug procurement may lead to a shrinking of traditional drug sales business; if the company's strategic transformation does not meet expectations, it will bring risks[55](index=55&type=chunk) - **Industry Competition Risk**: The apparel and pharmaceutical retail industries are highly competitive; if the company cannot adapt to market changes in terms of business model innovation and customer expansion, it may be at a disadvantage in competition[57](index=57&type=chunk) [Corporate Governance](index=20&type=section&id=第四节%20公司治理) This section outlines the company's corporate governance structure, including shareholder meetings, changes in key personnel, and profit distribution plans [Shareholders' Meeting and Changes in Directors, Supervisors, and Senior Management](index=20&type=section&id=股东大会情况说明) During the reporting period, the company held its 2023 Annual Shareholders' Meeting on June 28, 2024, where all 22 proposals were approved, and Ms. Liao Chen was elected as the new employee supervisor following Ms. Zhou Xin's resignation - The company held its 2023 Annual Shareholders' Meeting on June 28, 2024; the meeting procedures were legal and effective, and all proposals were approved[59](index=59&type=chunk)[60](index=60&type=chunk) - During the reporting period, there was a change in the company's employee supervisor: Ms. Zhou Xin resigned, and Ms. Liao Chen was elected as the new employee supervisor[61](index=61&type=chunk) [Profit Distribution Plan](index=20&type=section&id=三、利润分配或资本公积金转增预案) The company has no half-year profit distribution or capital reserve capitalization plan for this reporting period - No profit distribution or capital reserve capitalization plan for this reporting period[61](index=61&type=chunk) [Environmental and Social Responsibility](index=22&type=section&id=第五节%20环境与社会责任) This section details the company's environmental management practices and its commitment to social responsibility, including rural revitalization efforts and charitable contributions [Environmental Information](index=22&type=section&id=一、环境信息情况) The company is not a key pollutant discharge unit, with only its subsidiary Shibei Gaoxin Clinic involved in medical wastewater treatment and compliant discharge, and both the company and its main subsidiary are ISO14001 certified - The company is not a key pollutant discharge unit; its clinics handle medical wastewater according to regulations[63](index=63&type=chunk) - The company and its main subsidiaries hold valid "Environmental Management System Certification Certificates" (ISO14001)[64](index=64&type=chunk) [Social Responsibility and Rural Revitalization](index=23&type=section&id=二、巩固拓展脱贫攻坚成果、乡村振兴等工作具体情况) The company actively fulfills its social responsibilities as a state-owned enterprise, continuously carrying out targeted assistance work, including paired assistance projects with villages in Shanghai and Yunnan, and donating materials for charitable public welfare - The company continues to carry out rural revitalization assistance work, establishing paired assistance relationships with villages in Chongming District, Shanghai, Wenshan Prefecture, Yunnan, and other areas, and providing financial support[66](index=66&type=chunk) - The company's wholly-owned subsidiary, Shanghai Kaikai Shirt General Factory Co., Ltd., donated materials worth approximately **RMB 110,000** to the Shanghai Charity Foundation for charitable public welfare[66](index=66&type=chunk) [Significant Matters](index=24&type=section&id=第六节%20重要事项) This section covers significant events, including the fulfillment of commitments by key stakeholders, major related party transactions, and other important corporate developments [Fulfillment of Commitments](index=24&type=section&id=一、承诺事项履行情况) During the reporting period, the company's controlling shareholder, actual controller, and directors, supervisors, and senior management fulfilled commitments related to the refinancing project, and the controlling shareholder's long-term commitment regarding the "Zhang Chen Incident" bill dispute remains effective - To cooperate with the 2024 private placement of A-shares project, the controlling shareholder, Jing'an State-owned Assets Management Company, and the company's directors, supervisors, and senior management made commitments regarding share lock-up, filling immediate return dilution, etc[67](index=67&type=chunk)[68](index=68&type=chunk) - The controlling shareholder, Shanghai Kaikai (Group) Co., Ltd., issued a commitment letter in 2005 regarding the "Zhang Chen Incident" bill dispute, promising to bear all losses caused thereby, and this commitment remains long-term effective[69](index=69&type=chunk) [Significant Related Party Transactions](index=27&type=section&id=十、重大关联交易) During the reporting period, the company advanced a significant related party transaction, proposing to transfer its 10% equity stake in Shanghai Jing'an Yongshanghui Microfinance Co., Ltd. to its controlling shareholder, Kaikai Group, to optimize resource allocation and focus on its main business - The company plans to transfer its **10%** equity stake in Shanghai Jing'an Yongshanghui Microfinance Co., Ltd. to its controlling shareholder, Kaikai Group, with the transaction price determined based on asset appraisal results at **RMB 9.48452 million**[71](index=71&type=chunk) - This transaction has been approved by the SASAC and payment has been completed[72](index=72&type=chunk) [Other Significant Matters](index=29&type=section&id=十三、其他重大事项的说明) The company initiated a private placement of A-shares project in May 2024, which has been approved by the Shanghai State-owned Assets Supervision and Administration Commission and the company's shareholders' meeting, and is currently awaiting regulatory approval for implementation - The company's 2024 private placement of A-shares project has been approved by the Municipal SASAC and the shareholders' meeting, and is awaiting review and approval from regulatory authorities[75](index=75&type=chunk) [Share Changes and Shareholder Information](index=30&type=section&id=第七节%20股份变动及股东情况) This section provides an overview of the company's share capital stability and the composition of its shareholder base, including the controlling shareholder and top ten shareholders [Share Capital Changes](index=30&type=section&id=一、股本变动情况) During the reporting period, the company's total share capital and share capital structure remained unchanged, with a total share capital of **243 million shares** - During the reporting period, the company's total number of shares and share capital structure remained unchanged[77](index=77&type=chunk) [Shareholder Information](index=30&type=section&id=二、股东情况) As of the end of the reporting period, the company had **36,592** common shareholders, with the controlling shareholder, Shanghai Kaikai (Group) Co., Ltd., holding **26.51%** of the total share capital, and state-owned legal entities occupying multiple positions among the top ten shareholders - As of the end of the reporting period, the total number of common shareholders was **36,592**[78](index=78&type=chunk) Shareholder Information | Shareholder Name | Shares Held at Period End (Shares) | Proportion (%) | Shareholder Nature | | :--- | :--- | :--- | :--- | | Shanghai Kaikai (Group) Co., Ltd. | 64,409,783 | 26.51 | State-owned Legal Entity | | Shanghai Jing'an State-owned Assets Management Co., Ltd. | 6,000,000 | 2.47 | State-owned Legal Entity | | Shanghai Jinxing Trading Company | 3,000,000 | 1.23 | State-owned Legal Entity | | Yang Dexin | 2,539,200 | 1.04 | Domestic Natural Person | | CITIGROUP GLOBAL MARKETS LIMITED | 1,710,500 | 0.70 | Unknown | | Goldman Sachs & Co. LLC | 1,130,611 | 0.47 | Unknown | | Shanghai Jiubai (Group) Co., Ltd. | 880,000 | 0.36 | State-owned Legal Entity | | BOCI SECURITIES LIMITED | 862,725 | 0.36 | Unknown | | Jiang Yuping | 753,833 | 0.31 | Domestic Natural Person | | Zhou Bo | 700,000 | 0.29 | Domestic Natural Person | [Preferred Shares and Bonds](index=33&type=section&id=第八节%20优先股相关情况) This section confirms the absence of preferred shares, corporate bonds, convertible corporate bonds, and other non-financial enterprise debt financing instruments during the reporting period [Preferred Shares and Bonds](index=33&type=section&id=第八节%20优先股相关情况) During the reporting period, the company had no preferred shares, corporate bonds, convertible corporate bonds, or other non-financial enterprise debt financing instruments - The company has no preferred shares, corporate bonds, or convertible corporate bonds[81](index=81&type=chunk)[82](index=82&type=chunk) [Financial Report](index=35&type=section&id=第十节%20财务报告) This section presents the company's comprehensive financial statements, including balance sheets, income statements, cash flow statements, and notes, providing a detailed overview of its financial performance and position [Main Financial Statements](index=35&type=section&id=二、财务报表) This chapter includes the company's 2024 first-half consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owners' equity, comprehensively reflecting the financial status, operating results, and cash flow during the reporting period [Consolidated Balance Sheet](index=35&type=section&id=合并资产负债表) As of June 30, 2024, the company's total assets were **RMB 1.393 billion**, an increase of 4.96% from the beginning of the year; total liabilities were **RMB 754 million**, an increase of 4.75%; and net assets attributable to parent company shareholders were **RMB 615 million**, an increase of 3.21% | Item | June 30, 2024 (RMB) | December 31, 2023 (RMB) | | :--- | :--- | :--- | | **Total Assets** | **1,392,504,076.32** | **1,326,712,627.84** | | Total Current Assets | 790,733,280.13 | 728,570,642.19 | | Total Non-current Assets | 601,770,796.19 | 598,141,985.65 | | **Total Liabilities** | **753,668,434.99** | **719,515,141.16** | | Total Current Liabilities | 568,823,460.83 | 532,547,093.02 | | Total Non-current Liabilities | 184,844,974.16 | 186,968,048.14 | | **Total Owners' Equity Attributable to Parent Company** | **614,929,362.24** | **595,827,343.28** | [Consolidated Income Statement](index=39&type=section&id=合并利润表) In the first half of 2024, the company achieved total operating revenue of **RMB 490 million**, a year-on-year increase of 25.29%; total operating costs were **RMB 470 million**, an increase of 28.1%; net profit attributable to parent company shareholders was **RMB 31.009 million**, an increase of 83.25%, with basic earnings per share of **RMB 0.128** | Item | First Half of 2024 (RMB) | First Half of 2023 (RMB) | | :--- | :--- | :--- | | I. Total Operating Revenue | 489,520,495.53 | 390,695,063.33 | | II. Total Operating Costs | 469,570,674.02 | 366,585,535.95 | | III. Operating Profit | 54,515,615.68 | 26,048,617.31 | | IV. Total Profit | 54,866,860.45 | 26,079,655.91 | | Net Profit Attributable to Parent Company Shareholders | 31,009,018.96 | 16,921,435.33 | | Basic Earnings Per Share (RMB/share) | 0.128 | 0.070 | [Consolidated Cash Flow Statement](index=41&type=section&id=合并现金流量表) During the reporting period, net cash flow from operating activities was **-RMB 27.9344 million**, with a year-on-year increase in net outflow; investing activities turned into a net inflow of **RMB 25.8835 million** due to housing disposal funds; and financing activities had a net inflow of **RMB 0.6766 million** | Item | First Half of 2024 (RMB) | First Half of 2023 (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -27,934,426.71 | -20,721,631.19 | | Net Cash Flow from Investing Activities | 25,883,454.68 | -29,650,329.02 | | Net Cash Flow from Financing Activities | 676,570.72 | -19,065,786.41 | | Net Increase in Cash and Cash Equivalents | -1,373,510.81 | -69,605,371.28 | [Notes to Financial Statements (Selected)](index=69&type=section&id=七、合并财务报表项目注释) The notes provide detailed explanations of the composition and changes of major financial statement items, including the full impairment provision for receivables from Falcon Company, the large asset disposal gain recognized due to housing expropriation, and the breakdown of revenue by business type [Accounts Receivable](index=70&type=section&id=4、%20应收账款) The book value of accounts receivable at the end of the period was **RMB 413 million**, with **RMB 277 million** from Falcon International Group Limited fully impaired due to expected uncollectibility, and the top five accounts receivable collectively accounting for **83.02%** of the total - Accounts receivable from Falcon International Group Limited, amounting to **RMB 276,548,660.78**, have been fully impaired, with the reason being "expected to be uncollectible"[192](index=192&type=chunk) [Asset Disposal Gains](index=99&type=section&id=47、%20资产处置收益) Asset disposal gains for the reporting period were **RMB 28.4853 million**, a significant increase from **RMB 1,540.19** in the prior year, primarily from compensation received by wholly-owned subsidiary Shanghai Leiyunshang Pharmaceutical Xiqu Co., Ltd. due to its property being included in an old city renovation project - Current period asset disposal gains primarily resulted from the expropriation of property belonging to subsidiary Shanghai Leiyunshang Pharmaceutical Xiqu Co., Ltd., with total relocation compensation of **RMB 28.8774 million** received and **RMB 28.4393 million** recognized as asset disposal gains[263](index=263&type=chunk)[264](index=264&type=chunk) [Composition of Operating Revenue](index=95&type=section&id=37、%20营业收入和营业成本) The company's total operating revenue for the first half of 2024 was **RMB 490 million**, with the pharmaceutical segment contributing **RMB 459 million** as the absolute core revenue driver, and the apparel segment contributing **RMB 27.5 million**; wholesale revenue accounted for the highest proportion at **RMB 323 million** Revenue and Cost by Contract Classification | Contract Classification | Operating Revenue (RMB) | Operating Cost (RMB) | | :--- | :--- | :--- | | **By Business Segment** | | | | Pharmaceutical Segment | 458,900,923.01 | 374,246,913.29 | | Apparel Segment | 27,501,270.90 | 22,187,038.93 | | Other Segments | 3,118,301.62 | 752,695.38 | | **Total** | **489,520,495.53** | **397,186,647.60** |
开开B股(900943) - 2023 Q4 - 年度财报
2024-03-29 16:00
Financial Performance - The company achieved operating revenue of RMB 925.07 million in 2023, an increase of 3.46% compared to 2022[25]. - Net profit attributable to shareholders was RMB 39.30 million, a decrease of 1.57% from the previous year[26]. - The basic earnings per share remained at RMB 0.16, consistent with the previous year[25]. - The net cash flow from operating activities was RMB 578.43 thousand, a significant decrease of 99.27% compared to 2022[28]. - The weighted average return on equity decreased to 6.77%, down 0.49 percentage points from 2022[25]. - The company reported a total asset increase of 9.61% year-over-year, reaching RMB 1.33 billion by the end of 2023[25]. - Non-recurring gains and losses totaled RMB 29.85 million, compared to RMB 25.79 million in 2022[32]. - The company’s net assets attributable to shareholders increased by 4.77% to RMB 595.83 million[25]. - The gross profit margin decreased by 3.53 percentage points to 18.81% compared to the previous year[67]. - The company reported a significant decrease in cash flow from operating activities, with a net cash flow of RMB 578.43 thousand, down 99.27% year-on-year[64]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of RMB 0.49 per 10 shares to all shareholders, totaling RMB 11,907,000.00 (including tax) for the year 2023[7]. - The company does not plan to issue bonus shares or convert capital reserves into share capital for the current year[7]. - The company has maintained a consistent cash dividend policy, distributing dividends for 11 consecutive years, with a payout ratio exceeding 30% of the net profit each year[140]. - The total pre-tax compensation for the board members and senior management during the reporting period amounted to 3.8258 million CNY[116]. - The company has established effective communication channels with shareholders, holding two general meetings during the reporting period[111]. Governance and Compliance - The company has received a standard unqualified audit report from its accounting firm, ensuring the accuracy and completeness of the financial report[6]. - The board of directors has confirmed that all members attended the board meeting, ensuring proper governance and decision-making[5]. - The company emphasizes balancing the interests of shareholders, employees, and society while fulfilling social responsibilities[113]. - The company has revised its internal control system to enhance risk management and ensure compliance with regulatory requirements[113]. - The company continues to focus on governance and compliance with a well-structured board of directors[117]. Business Strategy and Development - The company plans to focus on the "big health" transformation strategy, aiming for high-quality development and optimizing its industrial structure[96]. - The pharmaceutical segment will leverage digital capabilities to transform its core businesses, focusing on "medicine, healthcare, and elderly care," while addressing challenges from recent healthcare reforms[101]. - The company is transitioning from traditional pharmaceutical retail to a focus on health services, integrating digital health initiatives into its business model[53]. - The company is committed to innovation-driven transformation and enhancing core competitiveness to achieve high-quality growth[108]. - The company is exploring partnerships with international firms to expand its product offerings in overseas markets[121]. Risk Management and Challenges - The company has outlined various risks and corresponding countermeasures in the management discussion and analysis section of the report[9]. - The pharmaceutical sector faces challenges due to price reductions from policies like two-invoice system and centralized procurement, prompting the company to explore a tri-wheel development strategy of "pharmaceuticals, medical care, and health care"[97]. - The company faces macroeconomic risks due to policy impacts on the retail sector, necessitating a focus on confidence-building and reform[106]. - The transformation efforts may face risks related to market uncertainty and the time required for new business models to mature, potentially impacting short-term profitability[107]. Product and Market Development - The company has introduced multiple new products, including Lingzhi spore powder and health teas, while its cultural brand "Yunshang Life" received awards for innovative products[39]. - The company has established the "Cloud Pharmacy" platform, connecting with 15 community health service centers to enhance drug delivery services, aiming for efficient and safe pharmaceutical services[38]. - The company has launched a comprehensive reform of its apparel sector, aiming to streamline management and enhance decision-making efficiency through the consolidation of subsidiaries[47]. - The company has introduced over 100 new products in the pharmaceutical retail sector, leveraging its supply chain advantages amid regulatory changes[44]. - The company is focusing on integrating traditional Chinese medicine with health services, exploring new business models in the healthcare sector[44]. Community and Environmental Responsibility - The company has committed approximately 600,000 yuan annually to support rural revitalization efforts in designated areas[49]. - The company invested CNY 5.08 million in environmental protection during the reporting period[149]. - The company has actively participated in community service and public welfare activities, promoting regional economic development[154]. - Total investment in poverty alleviation and rural revitalization projects amounted to 500,000 RMB[155]. Management and Organizational Structure - The company is led by a diverse team with extensive experience in various sectors, including finance, management, and law[117]. - The company has undergone several management changes, including the resignation of Gao Dongming and the retirement of Vice President Cen Zhijian[123]. - The company has implemented a training program focused on enhancing employee skills and knowledge to support sustainable development[137]. - The company has established a comprehensive internal control system that meets management requirements and ensures the authenticity and fairness of financial reporting[132]. Market Performance and Customer Engagement - The retail industry is experiencing a recovery, with consumer confidence steadily increasing, leading to a resurgence in demand[50]. - User data showed a 20% increase in active users, reaching 5 million by the end of the reporting period[120]. - The company is expanding its market presence, targeting a 25% increase in retail locations over the next year[121]. - The company’s clothing segment achieved a main business income of RMB 79.52 million, an increase of 16.29% year-on-year, with a gross margin of 7.54%[64].
开开实业:关于2023年半年度报告业绩说明会召开情况的公告
2023-09-07 09:14
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 | 股票代码:600272 900943 | | | | --- | --- | --- | | | 股票简称:开开实业 | 编号:2023—039 | | | 开开 B 股 | | 上海开开实业股份有限公司 关于 2023 年半年度报告业绩说明会召开情况的公告 上海开开实业股份有限公司(以下简称"公司")于 2023 年 9 月 7 日(星期四)下午 14:00-16:30 参加了"2023 年上海辖区上市公司 集体接待日暨中报业绩说明会"活动,以网络文字互动方式召开了公 司 2023 年半年度报告业绩说明会。关于本次业绩说明会的召开事项, 详见 2023 年 9 月 2 日在《上海证券报》《香港商报》和上海证券交 易所网站(www.sse.com.cn)上的公司《关于参加 2023 年上海辖区上 市公司集体接待日暨 2023 年半年度报告业绩说明会的公告》(公告 编号:2023-037)。现将召开情况公告如下: 一、业绩说明会召开情况 2023 年 9 月 7 日,公司董事、 ...